Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine

Neuropharmacology

Volumn 37, Issue 1, 1998, Pages 93-102

  Terry Jr , A V ^a   Williamson, R ^a   Gattu, M ^a   Beach, J W ^a   McCurdy, C R ^a   Sparks, J A ^b   Pauly, J R ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b University of Kentucky   (United States)

Author keywords

Acetycholine; Cholinergicy; Lobeline; Nicotine; Receptors

Indexed keywords

ACETYLCHOLINE; CRM I 13 1; CRM I 32 1; LOBELINE; LOBELINE DERIVATIVE; METHYLSCOPOLAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; CHOLINERGIC SYSTEM; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GILLES DE LA TOURETTE SYNDROME; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; SYNAPTOSOME;

ACETYLCHOLINESTERASE; ANIMALS; LOBELINE; NEOSTRIATUM; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, WISTAR; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; RUBIDIUM; SYNAPTOSOMES;

EID: 0031808433     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(97)00142-1     Document Type: Article

References (48)

1. Abood L.G., Salles K.S., Maiti A. Structure-activity studies of carbamate and other esters: agonists and antagonists to nicotine. Pharmacol. Biochem. Behav. 30:1988;403-408.
2. Aizenman E., Tang L.H., Reynolds I.J. Effects of nicotinic agonists on the NMDA receptor. Brain Res. 551:1991;355-357.
3. Arneric, S.P., Sullivan, J.P., Williams, M., 1995. Neuronal nicotinic acetylcholine receptors: novel targets for central nervous system therapeutics. In: Bloom, F.E., Kupfer, D.J. (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 95-110.
4. Bannon, A.W., Decker, M.W., Williams, M., Arneric, S.P., 1995. Psychotherapeutic potential of selective neuronal nicotinic acetylcholine receptor ligands. In: Domino, E.F. (Ed.). Brain Imaging of Nicotine and Tobacco Smoking. NPP Books, Ann Arbor, MI, pp. 311-334.
5. Barlow R.B., Johnson O. Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)-cytisine and (-)-lobeline hydrochloride and a comparison with (-)-nicotine and other nicotine-like compounds. Br. J. Pharmacol. 98:1989;799-808.
6. Barlow R.B., Franks F. Specificity of some ganglion stimulants. Br. J. Pharmacol. 42:1971;137-142.
7. Bhat R.V., Turner S.L., Selvaag S.R., Marks M.J., Collins A.C. Regulation of brain nicotinic receptors by chronic agonist infusion. J. Neurochem. 56:1991;1932-1939.
8. Brioni J.D., O'Neill A.B., Kim D.J., Decker M.W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur. J Pharmacol. 238:1993;1-8.
9. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliot K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors ha2b2, ha2b4, ha3b2, ha3b4, ha4b2, ha4b4 and ha7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 280:1997;346-356.
10. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
11. 3H]dopamine release. Br. J. Pharmacol. 117:1996;595-606.
12. Collins, A.C., Bhat, R.V., Pauly, J.R., Marks, M.J., 1990. Modulation of nicotine receptors by chronic exposure to nicotinic agonists and antagonists. In: Bn Book, G., Marsh, J. (Eds.). The Biology of Nicotine Dependence. John Wiley and Sons, Ciba Foundation Symposia, West Sussex, England, pp 68-86.
13. Court J.A., Perry E.K., Spurden D., Lloyd S., Gillespie J.I., Whiting P., Barlow R. comparison of the binding of nicotinic agonists to receptors from human and rat cerebral cortex and from chick brain (alpha 4 beta 2) transfected into mouse fibroblasts with ion channel activity. Brain Res. 667:1994;118-122.
14. Cachelin A.B., Rust G. B-subunits co-determine the sensitivity of rat neuronal nicotinic receptors to antagonists. Pflugers Arch. Eur. J. Physiol. 429:1995;449-451.
15. Decker M.W., Buckley M.J., Brioni J.D. Differential effects of pretreatment with nicotine and lobeline on nicotine-induced changes in body temperature and locomotor activity in mice. Drug Dev. Res. 31:1994;52-58.
16. Decker M.W., Majchrzak M.J., Arneric S.P. Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav. 45:1993;571-576.
17. Ellman G.L., Courtney K.D., Andres V. Jr., Featherstone R.B. A new rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
18. 2 subunits and is upregulated by chronic nicotine treatment. Mol. Pharmacol. 41:1992;31-37.
19. Gattu M., Terry A.V. Jr., Buccafusco J.J. A rapid microtechnique for the estimation of muscarinic and nicotinic receptor binding parameters using 96-well filtration plates. J. Neurosci. Methods. 63:1995;121-125.
20. Geller I., Hartmann R., Blum K. Effects of nicotine, nicotine monomethiodide, lobeline, chlordiazepoxide, meprobamate and caffeine on a discrimination task in laboratory rats. Psychopharmacologia. 20:1971;355-365.
21. 3H]dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59:1992;848-856.
22. Hussy N., Ballivet M., Bertrand D. Agonist and antagonist effects of nicotine on chick neuronal nicotinic receptors are defined by alpha-subunits and beta subunits. J. Neurophysiol. 72(3):1994;1317-1326.
23. Levin E.D. Nicotinic systems and cognitive function. Psychopharmacology. 108:1992;417-531.
24. Libri V., Das B., Constanti A. Ganglionic nicotinic receptor agonists exhibit antimuscarinic effects in guinea-pig olfactory cortical brain slices. Eur. J. Pharmacol. 212:1992;253-258.
25. 3H]nicotine to a single class of high affmity sites in rat brain membranes. Mol. Pharmacol. 29:1986;448-454.
26. Long, J.P., Eichler, O., Farah, A., 1966. Handbuch Der Experimentellen Pharmakologie. In: Long, J.P. (Ed.). Structure-activity relationships of the reversible anticholinesterase agents (chapter 8). Springer-Verlag, Berlin, pp. 393-425.
27. Marks M.J., Collins A.C. Characterization of nicotine binding in mouse brain and comparison with the binding of alpha-bungarotoxin and quinuclidinyl benzilate. Mol. Pharmacol. 22:1982;554-564.
28. Marks M.J., Farnharn D.A., Grady S.R., Collins A.C. Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes. J. Pharmacol. Exp. Ther. 264:1993;264-542.
29. + efflux from mouse brain synaptosomes. J. Pharmacol. Exp. Ther. 274:1995;1-9.
30. 3H](-)nicotine label the same recognition site in rat brain. Mol. Pharmacol. 31:1986;169-174.
31. Nachmansohn D. Sur l'action de la strychnine. C.R. Soc. Biol. 129:1938;941-943.
32. Reavill C., Walther B., Stolerman I.P., Testa B. Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacol. 7:1990;619-624.
33. 3H](-)nicotine to rat brain membranes and its inhibition by analogues of nicotine. Neuropharmacol. 27:1988;235-241.
34. Rochford J., Sen A.P., Quirion R. Effect of nicotine and nicotinic receptor agonists on latent inhibition in the rat. J. Pharmac. Exp. Ther. 277:1996;1267-1275.
35. Schechter M., Rosecrans J.A. Nicotine as a discriminative cue in rats: Inability of related drugs to produce a nicotine-like cueing effect. Psychopharmacologia. 27:1972;379-387.
36. Schmidt J. Drug binding properties of an alpha-bungarotoxin-binding component from rat brain. Mol. Pharmacol. 13:1977;283-290.
37. Seto Y., Shinohara T. Structure-activity relationship of reversible cholinesterase inhibitors including paraquat. Arch. Toxicol. 62:1988;37-40.
38. Sloan J.W., Martin W.R., Bostwick M., Hook R., Wala E. The comparative binding characteristics of nicotinic ligands and their pharmacology. Pharmac. Biochem. Behav. 30:1988;255-267.
39. Stolerman I.P., Garcha H.S., Mirza N.R. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology. 117:1995;430-437.
40. Sugimoto H., Iimura Y., Yamanishi Y., Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2yl)methyl] piperidine hydrochloride and related compounds. J. Med. Chem. 38:1995;4821-4829.
41. Sugimoto H., Tsuchiya Y., Sugumi H. et al. Novel piperidine derivatives. Synthesis and antiacetylcholinesterase activity of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine derivatives. J. Med. Chem. 33:1990;1880-1887.
42. + stimulation, methamphetamine and nicotinic drugs. Brain Res. 279:1983;330-334.
43. Taylor, P., 1990 Agents acting at the neuromuscular junction and autonomic ganglia. In: Goodman Gilman, A., Rall, T.W., Nies, A.S., Taylor, P. (Eds.). Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed. Pergamon, New York, pp. 166-186.
44. Taylor, P., 1996. Anticholinesterase agents. In: Taylor, P. (Ed.). Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 9th ed. Pergamon, New York, pp. 161-176.
45. Terry A.V. Jr., Buccafusco J.J., Jackson W.J., Zagrodnik S., Evans-Martin F.F., Decker M.W. Effects of stimulation or blockade of central nicotinic-cholinergic receptors on performance of a novel version of the rat stimulus discrimination task. Psychopharmacology. 123:1996;172-181.
46. Whiting P., Schoepfer R., Lindstrom J.T. Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol. Pharmacol. 40:1991;463-472.
47. Williams M., Robinson J.L. Binding of the nicotinic cholinergic antagonist, dihydro-betaerythroidine, to rat brain tissue. Neurosci. 4:1984;2906-2911.
48. Wonnacott, S., Wilkie, G., Soliakov, L., Whiteaker, P., 1995. Presynaptic nicotinic autoreceptors and heteroreceptors in the CNS. In: Clarke, P.B.S., Quik, M., Adlkofer, F., Thurau, K. (Eds.). Effects of Nicotine on Biological Systems, 2nd ed. Birkhauser Verlag, pp. 87-94.